ストックスクリーナーアプリを入手
32.60
2.44%
-0.815
アフターアワーズ：
32.60
前日終値:
$33.41
開ける：
$33.83
24時間の取引高:
161.93K
Relative Volume:
0.54
時価総額：
$1.64B
収益：
$357.71M
当期純損益:
$-20.10M
株価収益率:
-82.34
EPS:
-0.3959
ネットキャッシュフロー:
$28.67M
1週間 パフォーマンス:
-7.49%
1か月 パフォーマンス:
+0.80%
6か月 パフォーマンス:
+13.55%
1年 パフォーマンス:
-4.71%
1日の値動き範囲:
$32.47
$34.13
1週間の範囲:
$32.40
$35.45
52週間の値動き範囲:
$23.15
$39.33
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
名前
Immunocore Holdings Plc Adr
セクター
電話
01235 5430281
住所
90 PARK DRIVE, OXFORDSHIRE
IMCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
32.60 | 1.68B | 357.71M | -20.10M | 28.67M | -0.3959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 再開されました | Guggenheim | Neutral |
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2025-05-27 | 開始されました | Deutsche Bank | Buy |
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-10-24 | 開始されました | UBS | Sell |
| 2024-10-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-04-29 | 開始されました | Leerink Partners | Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 開始されました | Needham | Buy |
| 2023-08-16 | 開始されました | CapitalOne | Overweight |
| 2023-07-17 | 開始されました | Canaccord Genuity | Hold |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-03-30 | 開始されました | Guggenheim | Buy |
| 2023-03-24 | 開始されました | Bryan Garnier | Buy |
| 2022-12-16 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-30 | 開始されました | Barclays | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-08-08 | 開始されました | Cowen | Outperform |
| 2022-08-02 | 開始されました | BTIG Research | Buy |
| 2022-02-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-20 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | Goldman | Neutral |
| 2021-03-02 | 開始されました | JP Morgan | Overweight |
| 2021-03-02 | 開始されました | Jefferies | Buy |
すべてを表示
Immunocore Holdings Plc Adr (IMCR) 最新ニュース
Insider Selling: Immunocore (NASDAQ:IMCR) Insider Sells 22,532 Shares of Stock - MarketBeat
Immunocore (NASDAQ:IMCR) Now Covered by Analysts at Guggenheim - Defense World
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Cubist Systematic Strategies LLC Reduces Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Hold” by Analysts - Defense World
Banque Transatlantique SA Acquires Shares of 10,150 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Checkpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Baker BROS. Advisors LP Has $68.91 Million Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore (NASDAQ:IMCR) Stock Price Up 7.4%What's Next? - MarketBeat
Frazier Life Sciences Management L.P. Has $8.94 Million Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects - Investing.com India
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects By Investing.com - Investing.com South Africa
Immunocore Holdings plc ADR (NASDAQ: IMCR) Rises 9.33% In Recent Trading, What’s Next? - stocksregister.com
Immunocore (NASDAQ:IMCR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Earnings call transcript: Immunocore Q2 2025 beats revenue forecast - Investing.com
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $58.00 Consensus Price Target from Brokerages - Defense World
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - Defense World
FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright - Defense World
Immunocore’s SWOT analysis: stock outlook amid clinical milestones, market challenges - Investing.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - sharewise.com
Immunocore (IMCR) Q2 Revenue Jumps 30% - The Motley Fool
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Immunocore Holdings earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut - Yahoo Finance
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - sharewise.com
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Immunocore to Report Q2 2025 Financial Results on August 7, 2025 - AInvest
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - sharewise.com
Immunocore stock price target raised to $36 from $33 at Mizuho - Investing.com
Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89 - Defense World
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
The IMCR Stock Puzzle: Unraveling Immunocore Holdings plc ADR’s Fluctuating Performance - investchronicle.com
Can Mizuho Financial Group, Inc. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Principal Financial Group Inc. Reduces Stock Holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) - Defense World
Immunocore Holdings ADR Earns IBD Rating Upgrade - Investor's Business Daily
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - sharewise.com
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - sharewise.com
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment - Yahoo Finance
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease - Yahoo Finance
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag - Yahoo Finance
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer - Yahoo Finance
FDA Extends INCY's Application for Opzelura Label Expansion - Yahoo Finance
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Yahoo Finance
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study - Yahoo Finance
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion - Yahoo Finance
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Immunocore Holdings Plc Adr (IMCR) 財務データ
収益
当期純利益
現金流量
EPS
Immunocore Holdings Plc Adr (IMCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Sep 15 '25 |
Option Exercise |
17.46 |
200 |
3,492 |
200 |
| Berman David M | HEAD OF R&D |
Sep 12 '25 |
Sale |
35.67 |
22,532 |
803,699 |
0 |
| Berman David M | HEAD OF R&D |
Sep 15 '25 |
Sale |
35.01 |
200 |
7,002 |
0 |
| Berman David M | HEAD OF R&D |
Sep 10 '25 |
Option Exercise |
17.46 |
31,338 |
547,161 |
31,338 |
| Berman David M | HEAD OF R&D |
Sep 11 '25 |
Option Exercise |
17.46 |
19,081 |
333,154 |
19,081 |
| Berman David M | HEAD OF R&D |
Sep 10 '25 |
Sale |
36.14 |
31,338 |
1,132,709 |
0 |
| Berman David M | HEAD OF R&D |
Sep 11 '25 |
Sale |
36.28 |
19,081 |
692,259 |
0 |
1.43%
0.09%
大文字化:
|
ボリューム (24 時間):